Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

PHILADELPHIA, Feb. 4, 2013 (GLOBE NEWSWIRE) --

Hemispherx Biopharma, Inc.

(NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the US Food and Drug Administration ("FDA") declining to approve its new drug application ("NDA") for Ampligen®

for Chronic Fatigue Syndrome ("CFS"). The FDA said Hemispherx should conduct at least one additional

clinical trial, complete various nonclinical studies and perform a number of data analyses.

...more